Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has ...

DUBLIN, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable ...

Company begins roll out of innovative diabetes care HbA1c column system in Brazil Commercial leadership strengthened with key appointmentDUBLIN, ...

DUBLIN, June 24, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable ...

Clinical trial results support progression of CGM+ toward regulatory submissions and scaled commercialization - Anticipating initiation of pivotal clinical trial in 2026 - Updated electronics ...

Trinity Biotech plc announced that it has achieved Adjusted EBITDA-positive operations during Q2 2025 and expects to maintain this positive trajectory going forward, marking a key milestone in its ...

Trinity Biotech plc (NASDAQ: TRIB) stock surged Tuesday after the diagnostics company announced a pair of developments that significantly altered its near- and long-term outlook. Investors reacted ...

Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements. About Trinity Biotech Trinity Biotech is a commercial stage biotechnology company ...

Trinity Biotech is making a serious play in the continuous glucose monitoring space. The Dublin-based company announced positive clinical trial results demonstrating a major technical breakthrough and ...

The MarketWatch News Department was not involved in the creation of this content. - TrinScreen HIV order signals renewed strength in global HIV testing market - Company also reports a key milestone of ...